Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Chevron
CVX
|
+$317M |
| 2 |
Walmart Inc
WMT
|
+$218M |
| 3 |
Linde
LIN
|
+$174M |
| 4 |
PayPal
PYPL
|
+$133M |
| 5 |
Union Pacific
UNP
|
+$126M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$724M |
| 2 |
Uber
UBER
|
+$527M |
| 3 |
ExxonMobil
XOM
|
+$450M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$365M |
| 5 |
Apple
AAPL
|
+$336M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.8% |
| 2 | Healthcare | 17.12% |
| 3 | Consumer Discretionary | 13.21% |
| 4 | Financials | 8.81% |
| 5 | Consumer Staples | 7.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1951
Valhi
VHI
$388M
| $2.26M | ﹤0.01% |
131,717
-3,000
| -2% | -$43.1K |
|
|
WSR
1952
DELISTED
Whitestone REIT
WSR
| $2.26M | ﹤0.01% |
180,084
-72,294
| -29% | -$893K |
|
1953
AnaptysBio
ANAB
$1.63B
| $2.26M | ﹤0.01% |
100,200
+4,600
| +5% | +$109K |
|
1954
Emergent Biosolutions
EBS
$391M
| $2.25M | ﹤0.01% |
891,300
+344,000
| +63% | +$775K |
|
|
TDAY
1955
USA Today Co
TDAY
$1.32B
| $2.25M | ﹤0.01% |
923,500
-330,324
| -26% | -$742K |
|
1956
Curtiss-Wright
CW
$28B
| $2.25M | ﹤0.01% |
8,800
+900
| +11% | +$209K |
|
|
PHLT
1957
DELISTED
Performant Healthcare Inc
PHLT
| $2.25M | ﹤0.01% |
764,163
+1,800
| +0.2% | +$5.14K |
|
|
SLN
1958
Silence Therapeutics
SLN
$528M
| $2.24M | ﹤0.01% |
103,900
+76,798
| +283% | +$1.67M |
|
1959
Pacer Trendpilot US Large Cap ETF
PTLC
$3.37B
| $2.24M | ﹤0.01% |
47,000
+24,595
| +110% | +$1.12M |
|
1960
Xeris Biopharma Holdings
XERS
$1.41B
| $2.23M | ﹤0.01% |
1,009,340
-372,300
| -27% | -$963K |
|
1961
United Fire Group
UFCS
$1.38B
| $2.23M | ﹤0.01% |
102,338
+72,055
| +238% | +$1.6M |
|
1962
iShares MSCI Europe Financials ETF
EUFN
$4.27B
| $2.23M | ﹤0.01% |
97,900
-84,900
| -46% | -$1.79M |
|
1963
NeoGenomics
NEO
$2.09B
| $2.23M | ﹤0.01% |
141,600
+41,800
| +42% | +$645K |
|
1964
4D Molecular Therapeutics
FDMT
$536M
| $2.23M | ﹤0.01% |
+69,833
| New | +$1.78M |
|
1965
Astronics
ATRO
$3.73B
| $2.22M | ﹤0.01% |
140,040
-77,701
| -36% | -$1.16M |
|
1966
Capital Group Growth ETF
CGGR
$25.1B
| $2.22M | ﹤0.01% |
69,400
-43,900
| -39% | -$1.32M |
|
|
CTV
1967
DELISTED
Innovid Corp.
CTV
| $2.22M | ﹤0.01% |
891,481
+104,400
| +13% | +$181K |
|
1968
Invesco Total Return Bond ETF
GTO
$2.44B
| $2.21M | ﹤0.01% |
47,300
+28,938
| +158% | +$1.35M |
|
1969
First Trust Exchange-Traded Fund IV First Trust Tactical High Yield ETF
HYLS
$1.63B
| $2.21M | ﹤0.01% |
53,607
-16,093
| -23% | -$663K |
|
1970
Radcom
RDCM
$172M
| $2.21M | ﹤0.01% |
197,733
+41,700
| +27% | +$407K |
|
1971
First Trust Rising Dividend Achievers ETF
RDVY
$25.5B
| $2.2M | ﹤0.01% |
39,200
+12,600
| +47% | +$661K |
|
|
ADAP
1972
DELISTED
Adaptimmune Therapeutics
ADAP
| $2.2M | ﹤0.01% |
1,391,775
+21,536
| +2% | +$26K |
|
1973
iShares MSCI France ETF
EWQ
$342M
| $2.19M | ﹤0.01% |
53,000
-45,700
| -46% | -$1.81M |
|
1974
Grupo Cibest SA
CIB
$21.4B
| $2.19M | ﹤0.01% |
64,100
-37,700
| -37% | -$1.22M |
|
1975
TAT Technologies
TATT
$541M
| $2.19M | ﹤0.01% |
181,202
-1,400
| -0.8% | -$16.9K |
|
Similar funds
Renaissance Technologies's Q1 2024 Portfolio in Review
As of Q1 2024, Renaissance Technologies held 4,246 positions worth $63.6B, down 1.5% from $64.6B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies withdrew a net $5.25B in Q1 2024, closing 582 positions and reducing 1,517 holdings. Its most notable exit was ExxonMobil, an estimated $450M position sold in full.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Renaissance Technologies opened a new position in Chevron worth $331M.
- Renaissance Technologies's largest Q1 2024 buy was Chevron: 2,097,623 shares worth $331M.
- Renaissance Technologies added most to Walmart Inc in Q1 2024, an estimated $218M increase.
- Renaissance Technologies's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $724M.
- Renaissance Technologies fully exited ExxonMobil in Q1 2024, selling an estimated $450M.
- Renaissance Technologies's ten largest holdings make up 12% of its $63.6B portfolio in Q1 2024.
- Renaissance Technologies opened 563 new positions and closed 582 in Q1 2024.
- Renaissance Technologies's portfolio value fell 1.5% quarter-over-quarter to $63.6B.
Based on Renaissance Technologies's 13F filing for Q1 2024, filed 13 May 2024.